We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
-15.62%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.19B
AUM Growth
-$622M
Cap. Flow
-$278M
Cap. Flow %
-23.29%
Top 10 Hldgs %
72.62%
Holding
40
New
3
Increased
3
Reduced
19
Closed
3

Top Buys

Rank Stock Value
1
RVNC
Revance Therapeutics, Inc.
RVNC
+$10.9M
2
TVTX icon
Travere Therapeutics
TVTX
+$707K
3
URGN icon
UroGen Pharma
URGN
+$662K
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$620K
5
PBYI icon
Puma Biotechnology
PBYI
+$456K

Top Sells

Rank Stock Value
1
WMGI
Wright Medical Group Inc
WMGI
+$65.9M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$41.1M
3
UTHR icon
United Therapeutics
UTHR
+$39.2M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$23.1M
5
INSM icon
Insmed
INSM
+$18.8M

Sector Composition

Rank Sector Weight
1 Healthcare 87.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYTK icon
26
Cytokinetics
CYTK
$10.5B
$1.46M 0.12%
123,686
– –
ALIM
27
DELISTED
Alimera Sciences
ALIM
$804K 0.07%
200,919
– –
ZGNX
28
DELISTED
Zogenix, Inc.
ZGNX
$730K 0.06%
29,500
– –
SNDX icon
29
Syndax Pharmaceuticals
SNDX
$1.77B
$725K 0.06%
+66,100
New +$620K
TVTX icon
30
Travere Therapeutics
TVTX
$5.86B
$686K 0.06%
+47,000
New +$707K
ITCI
31
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$575K 0.05%
37,400
– –
VIRX
32
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$482K 0.04%
33,214
– –
URGN icon
33
UroGen Pharma
URGN
$2.39B
$437K 0.04%
+24,500
New +$662K
MRNS
34
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$254K 0.02%
31,330
– –
NERV icon
35
Minerva Neurosciences
NERV
$187M
$219K 0.02%
4,540
– –
ALDX icon
36
Aldeyra Therapeutics
ALDX
$91.7M
$182K 0.02%
73,500
– –
ACGN
37
DELISTED
Aceragen Inc
ACGN
$102K 0.01%
4,537
– –
GILD icon
38
Gilead Sciences
GILD
$168B
– –
-39,300
Closed -$2.55M
MLNT
39
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
– –
-10,137
Closed -$5K
SPHS
40
DELISTED
Sophiris Bio, Inc.
SPHS
– –
-247,000
Closed -$91K
1
2

Similar funds

AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
PCM
Primavera Capital Management George Town, Cayman Islands $648M AUM 6.1% 1-Year Est. Return
HCM
Huber Capital Management El Segundo, California $647M AUM 24.91% 1-Year Est. Return
ACM
Arosa Capital Management Miami Beach, Florida $660M AUM 210.26% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Palo Alto Investors's Q1 2020 Portfolio in Review

As of Q1 2020, Palo Alto Investors held 40 positions worth $1.19B, down 34% from $1.82B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Palo Alto Investors withdrew a net $278M in Q1 2020, closing 3 positions and reducing 19 holdings. Its most notable exit was Gilead Sciences, an estimated $2.55M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 84% a quarter earlier.

Against the trend, Palo Alto Investors opened a new position in Travere Therapeutics worth $686K.

  • Palo Alto Investors's largest Q1 2020 buy was Travere Therapeutics: 47,000 shares worth $686K.
  • Palo Alto Investors added most to Revance Therapeutics, Inc. in Q1 2020, an estimated $10.9M increase.
  • Palo Alto Investors's biggest Q1 2020 reduction was Wright Medical Group Inc, cutting an estimated $65.9M.
  • Palo Alto Investors fully exited Gilead Sciences in Q1 2020, selling an estimated $2.55M.
  • Palo Alto Investors's ten largest holdings make up 73% of its $1.19B portfolio in Q1 2020.
  • Palo Alto Investors opened 3 new positions and closed 3 in Q1 2020.
  • Palo Alto Investors's portfolio value fell 34% quarter-over-quarter to $1.19B.

Based on Palo Alto Investors's 13F filing for Q1 2020, filed 15 May 2020.